I repliced the deep learning model using the concepts of Natural Language Processing
behind the 2017 paper PubMed 200k RCT: a Dataset for Sequenctial Sentence Classification in Medical Abstracts.
To investigate the efficacy of @ weeks of daily low-dose oral prednisolone in improving pain , mobility , and systemic low-grade inflammation in the short term and whether the effect would be sustained at @ weeks in older adults with moderate to severe knee osteoarthritis ( OA ). A total of @ patients with primary knee OA were randomized @:@ ; @ received @ mg/day of prednisolone and @ received placebo for @ weeks. Outcome measures included pain reduction and improvement in function scores and systemic inflammation markers. Pain was assessed using the visual analog pain scale ( @-@ mm ). Secondary outcome measures included the Western Ontario and McMaster Universities Osteoarthritis Index scores , patient global assessment ( PGA ) of the severity of knee OA , and @-min walk distance ( @MWD )., Serum levels of interleukin @ ( IL-@ ) , IL-@ , tumor necrosis factor ( TNF ) - , and high-sensitivity C-reactive protein ( hsCRP ) were measured. There was a clinically relevant reduction in the intervention group compared to the placebo group for knee pain , physical function , PGA , and @MWD at @ weeks. The mean difference between treatment arms ( @ % CI ) was @ ( @-@ @ ) , p < @ ; @ ( @-@ @ ) , p < @ ; @ ( @-@ @ ) , p < @ ; and @ ( @-@ @ ) , p < @ , respectively. Further , there was a clinically relevant reduction in the serum levels of IL-@ , IL-@ , TNF - , and hsCRP at @ weeks in the intervention group when compared to the placebo group. These differences remained significant at @ weeks. The Outcome Measures in Rheumatology Clinical Trials-Osteoarthritis Research Society International responder rate was @ % in the intervention group and @ % in the placebo group ( p < @ ). Low-dose oral prednisolone had both a short-term and a longer sustained effect resulting in less knee pain , better physical function , and attenuation of systemic inflammation in older patients with knee OA ( ClinicalTrials.gov identifier NCT@ ).
'OBJECTIVE\tTo investigate the efficacy of @ weeks of daily low-dose oral prednisolone in improving pain , mobility , and systemic low-grade inflammation in the short term and whether the effect would be sustained at @ weeks in older adults with moderate to severe knee osteoarthritis ( OA ) .\n',
'METHODS\tA total of @ patients with primary knee OA were randomized @:@ ; @ received @ mg/day of prednisolone and @ received placebo for @ weeks .\n',
'METHODS\tOutcome measures included pain reduction and improvement in function scores and systemic inflammation markers .\n',
'METHODS\tPain was assessed using the visual analog pain scale ( @-@ mm ) .\n',
'METHODS\tSecondary outcome measures included the Western Ontario and McMaster Universities Osteoarthritis Index scores , patient global assessment ( PGA ) of the severity of knee OA , and @-min walk distance ( @MWD ) .\n',
'METHODS\tSerum levels of interleukin @ ( IL-@ ) , IL-@ , tumor necrosis factor ( TNF ) - , and high-sensitivity C-reactive protein ( hsCRP ) were measured .\n',
'RESULTS\tThere was a clinically relevant reduction in the intervention group compared to the placebo group for knee pain , physical function , PGA , and @MWD at @ weeks .\n',
'RESULTS\tThe mean difference between treatment arms ( @ % CI ) was @ ( @-@ @ ) , p < @ ; @ ( @-@ @ ) , p < @ ; @ ( @-@ @ ) , p < @ ; and @ ( @-@ @ ) , p < @ , respectively .\n',
'RESULTS\tFurther , there was a clinically relevant reduction in the serum levels of IL-@ , IL-@ , TNF - , and hsCRP at @ weeks in the intervention group when compared to the placebo group .\n',
'RESULTS\tThese differences remained significant at @ weeks .\n',
'RESULTS\tThe Outcome Measures in Rheumatology Clinical Trials-Osteoarthritis Research Society International responder rate was @ % in the intervention group and @ % in the placebo group ( p < @ ) .\n',
'CONCLUSIONS\tLow-dose oral prednisolone had both a short-term and a longer sustained effect resulting in less knee pain , better physical function , and attenuation of systemic inflammation in older patients with knee OA ( ClinicalTrials.gov identifier NCT@ ) .\n'